Atrial Fibrillation, Postoperative
Conditions
Keywords
post Operative Atrial Fibrillation, Arrhythmias, Cardiac Heart Diseases, Cardiovascular Diseases, Atrial Fibrillation, Anti-Arrhythmia Agents
Brief summary
The goal of this clinical trial is to is to test the safety of a new way to deliver a commonly used drug (amiodarone) used in heart surgery by placing a patch containing the drug directly on the heart instead of in an IV (vein). Participating subjects must be 20-85 year old males or females. Up to 80 participants having cardiac surgery at the University of Louisville will be involved in this study. The main questions this study aims to answer are: 1. Is the patch safe? 2. Does the patch lower the rate of atrial fibrillation (irregular heart rhythm) after cardiac surgery? Researchers will compare up to 3 different doses of the amiodarone patches (low, medium and high) to the usual treatment (Standard of Care) to see if there are differences (increases or decreases) in heart rhythms after cardiac surgery across study groups. Participants will be placed in one of 4 study groups: * Standard of Care (20 participants) * Low dose patch (20 participants) * Medium dose patch (20 participants) * High dose patch (20 participants) Participants will be monitored closely by their doctor(s) during the study and would: * Agree to participate after having their doctor, or a member of the team, explain the study in detail and allowing them to ask any questions they would like. * Sign an Informed Consent Form which will describe the study and tests in full. * Agree to have their doctor and his/her research team record your medical information, draw blood, and perform electrocardiograms, or EKGs (quick, painless test that measures the electrical activity of the heart) and echocardiograms (image of heart) to monitor their heart. * Agree to receive training on the portable EKG recorder and to use it at home approximately 30 days and 6 months after their surgery to monitor their heart. * Agree to return to the hospital approximately 30 days and 6 months after their surgery for a study visit. Participant involvement will be approximately 7 months total.
Detailed description
The purpose of this study is to determine the safety of a drug-device treatment for the prevention of postoperative atrial fibrillation following open heart surgery. Approximately a quarter of patients will develop atrial fibrillation after open heart surgery. Atrial fibrillation is a type of irregular heart rhythm or arrhythmia, in which the heart does not pump effectively. This can lead to problems such as stroke, palpitations (an abnormal heart rhythm that can feel like your heart is racing or pounding) and prolonged hospital stays. The goal of this study is to determine if the application of a medication (amiodarone) containing patch on the surface of the heart at the time of surgery is safe, which may lead to a treatment to lower the rate of atrial fibrillation in patients undergoing open heart surgery. The study drug-device is not yet FDA approved.
Interventions
COMBINATION_PRODUCTThe intervention includes Amiodarone-Infused CardiaMend patches (70mg, 150mg and 300mg)
Intervention includes a topical, atrial-specific, amiodarone infused CardiaMend patch in the operating room and applied onto the epicardial surface biatrially
Sponsors
Helios Cardio Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Caregiver)
Intervention model description
Subjects undergoing cardiac surgery via complete median sternotomy
Eligibility
Sex/Gender
ALL
Age
20 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* Subjects 20-85 years old. * Subjects able to give voluntary written informed consent, who understand and are willing to comply with study-related procedures. * Subjects scheduled to undergo open-chest cardiac surgery via complete median sternotomy. * Subjects in sinus rhythm at the time of office visit and during prior EKG (note: continuous EKG monitoring for 48 hours is not required).
Exclusion criteria
* Subjects unable to give voluntary written informed consent, unlikely to cooperate, or legally incompetent, including subjects institutionalized by court or official order, or in a dependency relationship with testing center or investigator. * Subjects with a condition that could interfere with their ability to comply with the study. * Subjects participating in an interventional clinical study or who have participated in such study during the preceding 30 days. * Female subjects who are pregnant, breastfeeding, were pregnant within the last three months, or are planning to become pregnant during the study. * Subjects with active skin or deep infection at the site of implantation. * Subjects with a history of chronic wounds or wound-healing disorders. * Subjects with known connective tissue diseases (e.g. Ehlers-Danlos syndrome, Epidermolysis bullosa, Marfan syndrome, Osteogenesis imperfecta). * Subjects who are Immune-suppressed or with immune deficiency (properly managed diabetes mellitus is not an exclusion criterion). * Subjects on concomitant oral or IV systemic corticosteroid therapy and/or other constant anti-inflammatory therapies. * Subjects on the following medications with known interactions with amiodarone: doxorubicin, fosphenytoin, lopinavir-ritonavir, ledipasvir/sofosbuvir, quinidine , procainamide, disopyramide, other Vaughan William class III agents including dofetilide, dronedarone, ibutilide and vernakalant. * Subjects with coadministration of any medications which cause QT prolongation * Subjects with implantable cardiac devices (i.e., cardiac resynchronization therapy devices with and without defibrillator capabilities (CRTs and CRT-Ds), implantable cardioverter-defibrillators (ICD), and pacemakers). * Subjects with a known history of atrial fibrillation or paroxysmal atrial fibrillation. * Subjects with a history of ablation for atrial fibrillation. * Subjects already receiving amiodarone as a treatment for atrial fibrillation or ventricular arrhythmias. * Subjects with a disease of the left pleura, previous intervention in the left pleural space, or chest deformity. * Subjects with heart failure (BNP\>1000), low ejection fraction (\<35%), end-stage renal disease (on dialysis or GFR\<20). * Subjects electing to receive an ablative procedure for atrial fibrillation during the index operation. * Subjects with prior cardiac surgery via sternotomy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety, defined as major adverse cardiac and cerebrovascular events (MACCE), up to subject discharge. | From the day of the index procedure up to two months or date of hospital discharge, whichever is the sooner | MACCE is defined as in-hospital all-cause death, acute myocardial infarction (AMI), or ischemic stroke. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Migration of cardiamend-amiodarone patches. | One day before the date of hospital discharge up to two months | Confirm placement of patches with non-contrast thoracic CT scan on first 3 subjects from Group 2 (70 mg) prior to discharge. |
| Length of Stay. | From the day of the index procedure to hospital discharge up to 2 months | Length of initial hospital stay. |
| Hospital readmission. | Up to 30 days post-subject hospital discharge. | 30 day readmission from discharge due to all cause complications based upon STS data |
| Incidence of postoperative atrial fibrillation (POAF) | From the day of the index procedure up to two months or date of hospital discharge, whichever is the sooner | Incidence of POAF up to patient discharge; defined as subject experiencing atrial fibrillation/flutter (AF) after OR Exit that lasted longer than one hour, or lasted less than one hour but required medical or procedural intervention. |
| Discharge on antiarrhythmic drug. | At subject hospital discharge to a maximum of 2 months post-index procedure date. | Discharge on antiarrhythmic drug, if POAF observed. |
| Discharge on oral anticoagulation. | At subject hospital discharge to a maximum of 2 months post-index procedure date. | Discharge on oral anticoagulation, if POAF observed. |
| POAF duration | From the day of the index procedure up to two months or date of hospital discharge, whichever is the sooner | Duration of POAF, if observed. |
Countries
United States
Contacts
Primary ContactJaimin Trivedi, MBBS FACC
Backup ContactChief Operating Officer, Helios Cardio Inc., PhD
Outcome results
None listed